Suppression of IL-12 production by tristetraprolin through blocking NF-κB nuclear translocation

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3922-3930

  Gu, Ling ^a   Ning, Huan ^a   Qian, Xuesong ^a   Huang, Qi ^a,b   Hou, Rong ^a   Almourani, Rajaa ^a   Fu, Mingui ^c   Blackshear, Perry J ^d   Liu, Jianguo ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 12P70; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TRISTETRAPROLIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; GENETIC TRANSCRIPTION; KNOCKOUT MOUSE; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RNA STABILITY; SEPTIC SHOCK; TH1 CELL;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL NUCLEUS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-12; MALE; MICE; MICE, KNOCKOUT; NF-KAPPA B; RNA, MESSENGER; SHOCK, SEPTIC; TH1 CELLS; TRANSCRIPTION, GENETIC; TRISTETRAPROLIN;

EID: 84885089440     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300126     Document Type: Article

References (46)

1. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827-845.
2. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-146.
3. Trinchieri, G. 1995. Interleukin-12:a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276.
4. Liu, J., X. Guan, T. Tamura, K. Ozato, and X. Ma. 2004. Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein. J. Biol. Chem. 279:55609-55617.
5. Liu, J., S. Cao, L. M. Herman, and X. Ma. 2003. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-γ-primed IL-12 production by IFN regulatory factor 1. J. Exp. Med. 198:1265-1276.
6. Schulz, O., A. D. Edwards, M. Schito, J. Aliberti, S. Manickasingham, A. Sher, and C. Reis e Sousa. 2000. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13:453-462.
7. Murphy, T. L., M. G. Cleveland, P. Kulesza, J. Magram, and K. M. Murphy. 1995. Regulation of interleukin 12 p40 expression through an NF-κB half-site. Mol. Cell. Biol. 15:5258-5267.
8. Ma, X., J. M. Chow, G. Gri, G. Carra, F. Gerosa, S. F. Wolf, R. Dzialo, and G. Trinchieri. 1996. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med. 183:147-157.
9. Plevy, S. E., J. H. Gemberling, S. Hsu, A. J. Dorner, and S. T. Smale. 1997. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol. Cell. Biol. 17:4572-4588.
10. Vermeire, K., H. Heremans, M. Vandeputte, S. Huang, A. Billiau, and P. Matthys. 1997. Accelerated collagen-induced arthritis in IFN-g receptor-deficient mice. J. Immunol. 158:5507-5513.
11. Grazia Cappiello, M., F. S. Sutterwala, G. Trinchieri, D. M. Mosser, and X. Ma. 2001. Suppression of Il-12 transcription in macrophages following Fcg receptor ligation. J. Immunol. 166:4498-4506.
12. Silverman, N., and T. Maniatis. 2001. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev. 15:2321-2342.
13. Perkins, N. D. 2007. Integrating cell-signalling pathways with NF-κB and IKK function. Nat. Rev. Mol. Cell Biol. 8:49-62.
14. Brasier, A. R. 2006. The NF-κB regulatory network. Cardiovasc. Toxicol. 6:111-130.
15. Gilmore, T. D. 2006. Introduction to NF-κB: players, pathways, perspectives. Oncogene 25:6680-6684.
16. Sanduja, S., F. F. Blanco, L. E. Young, V. Kaza, and D. A. Dixon. 2012. The role of tristetraprolin in cancer and inflammation. Front Biosci (Landmark Ed) 17:174-188.
17. Carballo, E., W. S. Lai, and P. J. Blackshear. 1998. Feedback inhibition of macrophage tumor necrosis factor-a production by tristetraprolin. Science 281:1001-1005.
18. Raghavan, A., R. L. Robison, J. McNabb, C. R. Miller, D. A. Williams, and P. R. Bohjanen. 2001. HuA and tristetraprolin are induced following T cell activation and display distinct but overlapping RNA binding specificities. J. Biol. Chem. 276:47958-47965.
19. Lai, W. S., E. Carballo, J. R. Strum, E. A. Kennington, R. S. Phillips, and P. J. Blackshear. 1999. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor a mRNA. Mol. Cell. Biol. 19:4311-4323.
20. Carballo, E., W. S. Lai, and P. J. Blackshear. 2000. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95:1891-1899.
21. Sawaoka, H., D. A. Dixon, J. A. Oates, and O. Boutaud. 2003. Tristetraprolin binds to the 39-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. J. Biol. Chem. 278:13928-13935.
22. Ogilvie, R. L., M. Abelson, H. H. Hau, I. Vlasova, P. J. Blackshear, and P. R. Bohjanen. 2005. Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. J. Immunol. 174:953-961.
23. Stoecklin, G., S. A. Tenenbaum, T. Mayo, S. V. Chittur, A. D. George, T. E. Baroni, P. J. Blackshear, and P. Anderson. 2008. Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin. J. Biol. Chem. 283:11689-11699.
24. Datta, S., R. Biswas, M. Novotny, P. G. Pavicic, Jr., T. Herjan, P. Mandal, and T. A. Hamilton. 2008. Tristetraprolin regulates CXCL1 (KC) mRNA stability. J. Immunol. 180:2545-2552.
25. Phillips, K., N. Kedersha, L. Shen, P. J. Blackshear, and P. Anderson. 2004. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis. Proc. Natl. Acad. Sci. USA 101:2011-2016.
26. Taylor, G. A., E. Carballo, D. M. Lee, W. S. Lai, M. J. Thompson, D. D. Patel, D. I. Schenkman, G. S. Gilkeson, H. E. Broxmeyer, B. F. Haynes, and P. J. Blackshear. 1996. A pathogenetic role for TNFα in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4:445-454.
27. Schichl, Y. M., U. Resch, R. Hofer-Warbinek, and R. de Martin. 2009. Tristetraprolin impairs NF-κB/p65 nuclear translocation. J. Biol. Chem. 284:29571-29581.
28. Liang, J., T. Lei, Y. Song, N. Yanes, Y. Qi, and M. Fu. 2009. RNA-destabilizing factor tristetraprolin negatively regulates NF-κB signaling. J. Biol. Chem. 284:29383-29390.
29. Jalonen, U., R. Nieminen, K. Vuolteenaho, H. Kankaanranta, and E. Moilanen. 2006. Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3α synthesis in activated macrophages. Mediators Inflamm. 2006:40691.
30. Qian, X., J. Zhang, and J. Liu. 2011. Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway. J. Biol. Chem. 286:2111-2120.
31. Lai, W. S., E. Carballo, J. M. Thorn, E. A. Kennington, and P. J. Blackshear. 2000. Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to AU-rich elements and destabilization of mRNA. J. Biol. Chem. 275:17827-17837.
32. Qian, X., H. Ning, J. Zhang, D. F. Hoft, D. J. Stumpo, P. J. Blackshear, and J. Liu. 2011. Posttranscriptional regulation of IL-23 expression by IFN-g through tristetraprolin. J. Immunol. 186:6454-6464.
33. Zhang, J., X. Qian, H. Ning, J. Yang, H. Xiong, and J. Liu. 2010. Activation of IL-27 p28 gene transcription by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1. J. Biol. Chem. 285:21269-21281.
34. Qiu, L. Q., D. J. Stumpo, and P. J. Blackshear. 2012. Myeloid-specific tristetraprolin deficiency in mice results in extreme lipopolysaccharide sensitivity in an otherwise minimal phenotype. J. Immunol. 188:5150-5159.
35. Schaljo, B., F. Kratochvill, N. Gratz, I. Sadzak, I. Sauer, M. Hammer, C. Vogl, B. Strobl, M. Müller, P. J. Blackshear, et al. 2009. Tristetraprolin is required for full antiinflammatory response of murine macrophages to IL-10. J. Immunol. 183:1197-1206.
36. Hodge-Dufour, J., M. W. Marino, M. R. Horton, A. Jungbluth, M. D. Burdick, R. M. Strieter, P. W. Noble, C. A. Hunter, and E. Puré. 1998. Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc. Natl. Acad. Sci. USA 95:13806-13811.
37. Ma, X., J. Sun, E. Papasavvas, H. Riemann, S. Robertson, J. Marshall, R. T. Bailer, A. Moore, R. P. Donnelly, G. Trinchieri, and L. J. Montaner. 2000. Inhibition of IL-12 production in human monocyte-derived macrophages by TNF. J. Immunol. 164:1722-1729.
38. Zakharova, M., and H. K. Ziegler. 2005. Paradoxical anti-inflammatory actions of TNF-a: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J. Immunol. 175:5024-5033.
39. Kastelein, R. A., C. A. Hunter, and D. J. Cua. 2007. Discovery and biology of IL-23 and IL-27:related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25:221-242.
40. Liu, J., G. Malkani, X. Shi, M. Meyer, S. Cunningham-Runddles, X. Ma, and Z. S. Sun. 2006. The circadian clock Period 2 gene regulates g interferon production of NK cells in host response to lipopolysaccharide-induced endotoxic shock. Infect. Immun. 74:4750-4756.
41. Suzuki, Y., M. A. Orellana, R. D. Schreiber, and J. S. Remington. 1988. Interferon-g: the major mediator of resistance against Toxoplasma gondii. Science 240:516-518.
42. Anderson, P. 2008. Post-transcriptional control of cytokine production. Nat. Immunol. 9:353-359.
43. Bakheet, T., M. Frevel, B. R. Williams, W. Greer, and K. S. Khabar. 2001. ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res. 29:246-254.
44. Baeuerle, P. A., and T. Henkel. 1994. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:141-179.
45. Liu, J., and X. Ma. 2006. Interferon regulatory factor 8 regulates RANTES gene transcription in cooperation with interferon regulatory factor-1, NF-κB, and PU.1. J. Biol. Chem. 281:19188-19195.
46. Liu, J., X. Guan, and X. Ma. 2007. Regulation of IL-27 p28 gene expression in macrophages through MyD88-and interferon-γ-mediated pathways. J. Exp. Med. 204:141-152.